Trudell Medical International has announced publication of a retrospective study that found a 13% reduction in emergency room visits for patients using a metered dose inhaler with the company’s AeroChamber Plus Flow-Vu Anti-Static valved holding chamber (VHC) compared to patients using non-anti-static holding chambers.
The study, published in Pulmonary Therapy in December 2017, found that patients using the AeroChamber Plus also experienced significantly longer time to first exacerbation and a non-significant 19% reduction in hospitalizations.
The AeroChamber Plus Flow-Vu Anti-Static VHC has been available by prescription in the UK since in November 2017.
Trudell Medical UK Regional Head Alan Clark commented, “At Trudell Medical UK Limited we aim to bring innovative solutions to real-life problems, unlocking improved outcomes for respiratory patients. The current NHS crisis is exacerbated by patients presenting to A&E with respiratory problems that often get worse in winter. Our new AeroChamber Plus Flow-Vu Anti-Static VHC may reduce some of the 121,000 A&E attendances made by asthma patients every year in the UK. A 13% reduction may mean 15,730 fewer visits to A&E by asthma patients each year. Furthermore, if all people with asthma currently using a pMDI plus VHC in the UK were switched to the AeroChamber Plus Flow-Vu Anti-Static VHC, our budget impact model shows that in one year the UK health system could reallocate £7.2m of healthcare resources to other areas of need due to reduced demand by patients with asthma.”
Trudell Medical International Group Director of Global Science and Technology Jason Suggett, who co-authored the study, said, “The European Medicines Agency recommended in 2009 that development of a pMDI should include the testing of at least one specific named chamber, and that any substitution must be supported by appropriate in vitro or clinical data demonstrating equivalence. We presented laboratory data at the recent Respiratory Drug Delivery Europe meeting that confirmed that not all chambers perform equally well with the same pMDI, which underlines the importance of recognizing the impact and potential risks of substituting one device for another.”
Read the Trudell Medical press release.
